Corona virus disease 2019 (COVID 19), first identified in December 2019 in a cluster of population in a Chinese province, soon emerged as a pandemic, causing a huge strain on healthcare system and mortality all over the world. An ideal marker for predicting course of this illness should be easily available and reproducible; as the disease burden has spread to third world countries whose healthcare system is resource limited. Our study is aimed to study the utility of lymphocyte- monocyte ratio in the early stages to predict the progression of COVID 19 pneumonia.
Diagnostic Test: LYMPHOCYTE MONOCYTE RATIO
Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.
Inclusion Criteria:
- All adults of age 18-80 years tested positive for SARS-CoV-2 reverse-transcriptase -
polymerase chain reaction (rt-PCR) and presented within 7 days of symptom(s) onset
Exclusion Criteria:
- Pregnancy
- Sepsis
- Malignancy
- Patients on immunosuppressant therapy
- Chronic inflammatory conditions
- Cases lost to follow up
Sir Ganga Ram Hospital
New delhi, Delhi, India